15 reports

  • Products & Markets
  • TECHNOLOGY & SYSTEMS

Scientific advances in genetic coding and neural mapping of the brain have helped doctors and researchers in this field recognize patterns associated with certain disorders.

  • Addictions
  • Mental Health
  • Psychoactive Drug Consumption
  • Canada
  • Forecast
  • Products & Markets

Factors influencing the level of such disorders include the prevalence of birth and genetic defects; accidents involving head injuries (including from road accidents); illicit drugs and alcohol; age (i. e. dementia); family abuse; and anxiety.

  • Addictions
  • Mental Health
  • Psychoactive Drug Consumption
  • United States
  • Forecast

The incidence of such disorders is influenced by birth and genetic defects, accidents involving head injuries (including from road accidents), disease, substance abuse, age (dementia), the level of anxiety in the community (as influenced by work and other social and environmental factors) a

  • Addictions
  • Hospital
  • Specialty Hospital
  • United States
  • Forecast
  • Products & Markets

Population with mental disorders or substance abuse The number of psychiatric and substance abuse disorders in a community varies by geographic area and is also influenced by birth and genetic defects, accidents involving head injuries, the availability and acceptance of illicit drugs and a

  • Addictions
  • Mental Health
  • Psychoactive Drug Consumption
  • United States
  • Forecast
  • Products & Markets

Genetic predisposition In October 2012, McGill researchers found a connection between a gene Consumers aged ## to ## Individuals aged ## to ## are estimated to account for ##. ##% of total revenue, making them the largest market for operators in the Mental Health and Substance Abuse Centres i

  • Addictions
  • Mental Health
  • Psychoactive Drug Consumption
  • Canada
  • Forecast

However, researchers have established that biological factors, especially genetic aspects, play an important role.

  • Addictions
  • World
  • Actavis plc
  • Allergan plc
  • Pfizer Inc.
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database

Component ## Naltrexone Effects on Alcohol Reactivity and Consumption, Evaluating the Genetic Variability of Naltrexone Response Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.

  • Addictions
  • Neurology
  • United States
  • World
  • Alkermes plc
  • Prominent Drugs

Component ## Naltrexone Effects on Alcohol Reactivity and Consumption, Evaluating the Genetic Variability of Naltrexone Response Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.

  • Addictions
  • Neurology
  • United States
  • World
  • Alkermes plc

The company primarily invests in healthcare themes such as prevention and cures; cost effective diagnostics and interventions; genetic testing and personalized medicine; nurse-enabling technologies; patient / physician convenience; and small-molecule replacements for biologics.

  • Addictions
  • Psychotic Disorder
  • United States
  • Company Financials
  • Alkermes plc

When paired with genetic test to focus on the most appropriate patients, AD## was found to significantly reduce days of drinking in patients with certain genotypes.

  • Addictions
  • Pharmaceutical
  • United States
  • Product Initiative
  • MediciNova, Inc.
  • SMALL MOLECULE TO ANTAGONIZE NMDA RECEPTOR AND BLOCK SODIUM CHANNELS FOR CNS DISORDERS - DRUG PROFILE
  • ONDANSETRON HYDROCHLORIDE - DRUG PROFILE

When paired with genetic test to focus on the most appropriate patients, AD## was found to significantly reduce days of drinking in patients with certain genotypes.

  • Addictions
  • Pharmaceutical
  • United States
  • Product Initiative
  • MediciNova, Inc.
  • DRUG ADDICTION - PIPELINE BY OREXIGEN THERAPEUTICS INC
  • DRUG ADDICTION - PIPELINE BY P2D BIOSCIENCE

Ronald Crystal, chairman of the Department of Genetic Medicine at Weill Cornell Medicine and a pulmonologist at NewYork-Presbyterian/ Weill Cornell Medical Center.

  • Addictions
  • United States
  • Company
  • Product Initiative
  • Omeros Corporation
  • DRUG ADDICTION - PIPELINE BY OREXIGEN THERAPEUTICS INC, H2 2017
  • DRUG ADDICTION - PIPELINE BY P2D BIOSCIENCE, H2 2017

P##D Bioscience (P##D) is a pharmaceutical company that develops drugs for genetic orphan diseases.

  • Addictions
  • Opioid
  • Therapy
  • United States
  • Product Initiative
  • DRUG ADDICTION - PIPELINE BY SANIONA AB, H1 2018
  • DRUG ADDICTION - PIPELINE BY P2D BIOSCIENCE, H1 2018

DRUG ADDICTION - PIPELINE BY OMEROS CORP, H## 2018 OREXIGEN THERAPEUTICS INC DRUG ADDICTION - PIPELINE BY OREXIGEN THERAPEUTICS INC, H## 2018 P##D Bioscience (P##D) is a pharmaceutical company that develops drugs for genetic orphan diseases.

  • Addictions
  • Opioid
  • Therapy
  • United States
  • Product Initiative
  • ADDICTION - PIPELINE BY LOHOCLA RESEARCH CORPORATION, H2 2015
  • LOHOCLA RESEARCH CORPORATION

Its products include kin-dolor, genetic marker and genetic markers used for alcoholism and smoking cessation.

  • Addictions
  • Research And Development
  • United States
  • Company
  • Product Initiative